Drug intelligence / Profile preview

Kelu Oral Liquid

Development stage: Unknown
Lead developer: Buchang Pharmaceuticals
Administration: Oral

Overview

Kelu Oral Liquid is a Traditional Chinese Medicine (TCM) product developed and manufactured by Shanxi Buchang Pharmaceutical. It is primarily indicated for the treatment of cough and various respiratory diseases, including bronchitis and upper respiratory tract infections. As a TCM formulation, it typically functions through antitussive, expectorant, and anti-inflammatory actions to relieve symptoms associated with lung-heat or wind-heat patterns. It is approved for marketing in China and is administered as an oral solution.

Brand names: Kelu
Other names: Kelu Koufuye

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)AR (Adrenergic receptors)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on Kelu Oral Liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelu Oral Liquid.

Explore the full profile